A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

Giovanni Palladini; Ernesto Anesi; Vittorio Perfetti; Laura Obici; Rosangela Invernizzi; Carlo Balduini; Edoardo Ascari; Giampaolo Merlini

doi:10.1046/j.1365-2141.2001.02859.x

A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

Giovanni Palladini, Ernesto Anesi, Vittorio Perfetti, Laura Obici, Rosangela Invernizzi, Carlo Balduini, Edoardo Ascari, Giampaolo Merlini

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

High-dose dexamethasone (HD-Dex) has been reported to benefit AL amyloidosis patients with varying response rates. Our preliminary experience with the usual HD-Dex schedule indicated that the induction phase was rather toxic in AL patients. We therefore adopted a milder schedule consisting of dexamethasone 40 mg on d 1-4 q21 d for up to eight cycles. Overall 8 out of 23 (35%) treated patients responded to treatment in a median time of 4 months (range 2-6 months) without significant toxicity. This regimen may be considered front-line therapy when autologous stem cell transplantation is not feasible and when a rapid response is particularly important.

Original language	English
Pages (from-to)	1044-1046
Number of pages	3
Journal	British Journal of Haematology
Volume	113
Issue number	4
DOIs	https://doi.org/10.1046/j.1365-2141.2001.02859.x
Publication status	Published - 2001

Keywords

AL amyloidosis
High-dose dexamethasone
Response time
Survival

ASJC Scopus subject areas

Hematology

Access to Document

10.1046/j.1365-2141.2001.02859.x

Fingerprint Dive into the research topics of 'A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis'. Together they form a unique fingerprint.

Cite this

A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. / Palladini, Giovanni; Anesi, Ernesto; Perfetti, Vittorio; Obici, Laura ; Invernizzi, Rosangela; Balduini, Carlo; Ascari, Edoardo; Merlini, Giampaolo.

In: British Journal of Haematology, Vol. 113, No. 4, 2001, p. 1044-1046.

Research output: Contribution to journal › Article › peer-review

@article{12619db3509b43c5aef9e3abc59b8c15,

title = "A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis",

abstract = "High-dose dexamethasone (HD-Dex) has been reported to benefit AL amyloidosis patients with varying response rates. Our preliminary experience with the usual HD-Dex schedule indicated that the induction phase was rather toxic in AL patients. We therefore adopted a milder schedule consisting of dexamethasone 40 mg on d 1-4 q21 d for up to eight cycles. Overall 8 out of 23 (35%) treated patients responded to treatment in a median time of 4 months (range 2-6 months) without significant toxicity. This regimen may be considered front-line therapy when autologous stem cell transplantation is not feasible and when a rapid response is particularly important.",

keywords = "AL amyloidosis, High-dose dexamethasone, Response time, Survival",

author = "Giovanni Palladini and Ernesto Anesi and Vittorio Perfetti and Laura Obici and Rosangela Invernizzi and Carlo Balduini and Edoardo Ascari and Giampaolo Merlini",

year = "2001",

doi = "10.1046/j.1365-2141.2001.02859.x",

language = "English",

volume = "113",

pages = "1044--1046",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons, Ltd (10.1111)",

number = "4",

}

TY - JOUR

T1 - A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

AU - Palladini, Giovanni

AU - Anesi, Ernesto

AU - Perfetti, Vittorio

AU - Obici, Laura

AU - Invernizzi, Rosangela

AU - Balduini, Carlo

AU - Ascari, Edoardo

AU - Merlini, Giampaolo

PY - 2001

Y1 - 2001

N2 - High-dose dexamethasone (HD-Dex) has been reported to benefit AL amyloidosis patients with varying response rates. Our preliminary experience with the usual HD-Dex schedule indicated that the induction phase was rather toxic in AL patients. We therefore adopted a milder schedule consisting of dexamethasone 40 mg on d 1-4 q21 d for up to eight cycles. Overall 8 out of 23 (35%) treated patients responded to treatment in a median time of 4 months (range 2-6 months) without significant toxicity. This regimen may be considered front-line therapy when autologous stem cell transplantation is not feasible and when a rapid response is particularly important.

AB - High-dose dexamethasone (HD-Dex) has been reported to benefit AL amyloidosis patients with varying response rates. Our preliminary experience with the usual HD-Dex schedule indicated that the induction phase was rather toxic in AL patients. We therefore adopted a milder schedule consisting of dexamethasone 40 mg on d 1-4 q21 d for up to eight cycles. Overall 8 out of 23 (35%) treated patients responded to treatment in a median time of 4 months (range 2-6 months) without significant toxicity. This regimen may be considered front-line therapy when autologous stem cell transplantation is not feasible and when a rapid response is particularly important.

KW - AL amyloidosis

KW - High-dose dexamethasone

KW - Response time

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0034944620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034944620&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.02859.x

DO - 10.1046/j.1365-2141.2001.02859.x

M3 - Article

C2 - 11442500

AN - SCOPUS:0034944620

VL - 113

SP - 1044

EP - 1046

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -